SAB Biotherapeutics (SABS) Earnings Date & Reports

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SABS is expected to report earnings to -28 cents per share on November 17

SAB Biotherapeutics SABS Stock Earnings Reports

Q3'26

Est.

$-0.28

Q2'26

Missed

by $0.01

Q1'26

Beat

by $0.23

Q4'25

Missed

by $0.13

Q3'25

Missed

by $0.09

The last earnings report on August 06 showed earnings per share of -28 cents, missing the estimate of -26 cents. With 99.61K shares outstanding, the current market capitalization sits at 336.19M.

View a ticker or compare two or three

SABS

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days